These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 26621619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N, Sevillano D, Alou L, Cafini F, Gimenez MJ, Gomez-Lus ML, Prieto J, Aguilar L.
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [Abstract] [Full Text] [Related]

  • 8. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ, Leonard SN, Vilay AM, Mercier RC.
    Clin Ther; 2014 Oct 01; 36(10):1334-44. PubMed ID: 25066667
    [Abstract] [Full Text] [Related]

  • 9. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT.
    Antimicrob Agents Chemother; 2015 Dec 28; 60(3):1584-91. PubMed ID: 26711763
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Houlihan HH, Mercier RC, Rybak MJ.
    Antimicrob Agents Chemother; 1997 Nov 28; 41(11):2497-501. PubMed ID: 9371356
    [Abstract] [Full Text] [Related]

  • 16. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
    Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.
    Int J Antimicrob Agents; 2011 Mar 28; 37(3):219-24. PubMed ID: 21239146
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
    Harigaya Y, Bulitta JB, Forrest A, Sakoulas G, Lesse AJ, Mylotte JM, Tsuji BT.
    Antimicrob Agents Chemother; 2009 Sep 28; 53(9):3894-901. PubMed ID: 19596879
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST, Sutherland CA, Nicolau DP.
    Int J Antimicrob Agents; 2014 Sep 28; 44(3):235-41. PubMed ID: 25052866
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.